- An Updated Follow-Up of BRL-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer for Transfusion-Dependent β-thalassemiaFu, Bin; Zhang, Xinhua; Wang, Li; Liao, Jiaoyang; Chen, Shuanghong; Zheng, Biao; Li, Wei; Wang, Fei; Li, Dali; Liu, Mingyao; Wu, Yuxuan
- Therapeutic genome editing of an aberrant splice site in β-thalassemia by CRISPR/Cas9 with multiple sgRNAsYang, Fei; Xu, Shuqian; Huang, Chao; Shao, Zhiqiang; Hu, Yuefen; Yang, Yang; Lai, Yongrong; Ke, Qing; Liang, Dan*; Wu, Yuxuan*Genes & Diseases, 2024, 11(1): 15-18.
- Safety and Efficacy of RM-001 (Autologous HBG1/2 Promoter-modified CD34+Hematopoietic Stem and Progenitor Cells) in Patients with Transfusion-Dependent βThalassemiaLiu, Rongrong; Wang, Li; Xu, Hui; Yin, Xiaolin; Liang, Junbin; Xie, Wenqiang; Yang, Gaohui; Li, Yaoyun; Zhou, Yali; Shi, Lei; Xiao, Bin; Shi, Lingling; Shi, Zeyan; Zhou, Xuemei; Xu, Xiangmin; Fang, Jianpei; Lai, Yongrong; Huang, Junjiu; Zhang, Xinhua65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
会议论文
Efficacy and Safety of Brl-101, CRISPR-Cas9-Mediated Gene Editing of the BCL11A Enhancer in Transfusion-Dependent β-Thalassemia
3阅读
